JP2009543885A - イブプロフェンの投与のための方法および医薬 - Google Patents

イブプロフェンの投与のための方法および医薬 Download PDF

Info

Publication number
JP2009543885A
JP2009543885A JP2009520962A JP2009520962A JP2009543885A JP 2009543885 A JP2009543885 A JP 2009543885A JP 2009520962 A JP2009520962 A JP 2009520962A JP 2009520962 A JP2009520962 A JP 2009520962A JP 2009543885 A JP2009543885 A JP 2009543885A
Authority
JP
Japan
Prior art keywords
famotidine
ibuprofen
dosage form
administration
unit dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009520962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543885A5 (enExample
Inventor
ジョージ ティドマーシュ，
バリー エル． ゴロンビク，
プニート シャルマ，
Original Assignee
ホライゾン セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/489,269 external-priority patent/US20080021078A1/en
Priority claimed from US11/489,272 external-priority patent/US20080020040A1/en
Application filed by ホライゾン セラピューティクス， インコーポレイテッド filed Critical ホライゾン セラピューティクス， インコーポレイテッド
Publication of JP2009543885A publication Critical patent/JP2009543885A/ja
Publication of JP2009543885A5 publication Critical patent/JP2009543885A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009520962A 2006-07-18 2007-07-17 イブプロフェンの投与のための方法および医薬 Pending JP2009543885A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/489,269 US20080021078A1 (en) 2006-07-18 2006-07-18 Methods and medicaments for administration of ibuprofen
US11/489,272 US20080020040A1 (en) 2006-07-18 2006-07-18 Unit dose form for administration of ibuprofen
US89737107P 2007-01-24 2007-01-24
PCT/US2007/073716 WO2008011426A2 (en) 2006-07-18 2007-07-17 Methods and medicaments for administration of ibuprofen

Publications (2)

Publication Number Publication Date
JP2009543885A true JP2009543885A (ja) 2009-12-10
JP2009543885A5 JP2009543885A5 (enExample) 2011-08-11

Family

ID=38957561

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009520962A Pending JP2009543885A (ja) 2006-07-18 2007-07-17 イブプロフェンの投与のための方法および医薬

Country Status (13)

Country Link
EP (2) EP2043637B8 (enExample)
JP (1) JP2009543885A (enExample)
AT (1) ATE539747T1 (enExample)
AU (1) AU2007275360B2 (enExample)
BR (1) BRPI0714937A2 (enExample)
CA (1) CA2657928C (enExample)
DK (1) DK2043637T3 (enExample)
ES (1) ES2380747T3 (enExample)
IL (1) IL196425A (enExample)
NZ (1) NZ574200A (enExample)
PL (1) PL2043637T3 (enExample)
PT (1) PT2043637E (enExample)
WO (1) WO2008011426A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534810A (ja) * 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物
JP2024514989A (ja) * 2021-10-21 2024-04-03 ハン ファ ファーマ カンパニー、リミテッド モンテルカストまたはその薬学的に許容可能な塩、及びレボセチリジンまたはその薬学的に許容可能な塩を含有する、安定性が改善されたフィルムコーティング錠剤

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
WO2008091957A2 (en) * 2007-01-24 2008-07-31 Horizon Therapeutics, Inc. Pharmaceutical compositions containing famotidine and ibuprofen and having improved content uniformity
WO2013054352A1 (en) 2011-08-17 2013-04-18 Cadila Healthcare Limited Pharmaceutical compositions of ibuprofen and famotidine
PL2912193T3 (pl) 2012-10-29 2019-03-29 Arizona Board Of Regents On Behalf Of University Of Arizona Markery predykcyjne dla terapii przeciwnowotworowej z użyciem inhibitora poliaminy
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
CA2952771A1 (en) 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
WO2017075576A1 (en) * 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
KR20180069068A (ko) 2015-10-30 2018-06-22 캔서 프리벤션 파마수티컬스, 인코포레이티드 에플로르니틴 및 설린닥, 고정된 용량 조합 제제
US10945981B2 (en) 2019-05-17 2021-03-16 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
CA3124579A1 (en) 2020-07-15 2022-01-15 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502254A (ja) * 1992-09-29 1996-03-12 メルク エンド カンパニー インコーポレーテッド イブプロフェン−ｈ▲下２▼拮抗薬配合物
JP2004536809A (ja) * 2001-06-01 2004-12-09 ポーゼン インコーポレイテッド Ｎｓａｉｄを協調的に送達するための薬剤組成物
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056143B2 (ja) 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4802924A (en) 1986-06-19 1989-02-07 Colorcon, Inc. Coatings based on polydextrose for aqueous film coating of pharmaceutical food and confectionary products
HU196775B (en) 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
US5976578A (en) * 1996-10-10 1999-11-02 Mcneil-Ppc, Inc. Liquid antacid compositions
US6251945B1 (en) 1999-01-14 2001-06-26 Knoll Aktiengesellschaft Pharmaceutical mixture comprising a combination of a profen and other active compounds
DE10003757A1 (de) 2000-01-28 2001-08-02 Knoll Ag Ibuprofen-Wirkstoffzubereitung
DE10153934A1 (de) 2001-11-06 2003-05-22 Basf Ag Verfahren zur Kristallisation von Profenen
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
EP1919288A4 (en) * 2005-07-18 2009-12-16 Horizon Therapeutics Inc MEDICAMENTS CONTAINING FAMOTIDINE AND IBUPROFEN, AND ADMINISTRATION OF SAID DRUGS
DE102005049001A1 (de) 2005-10-11 2007-04-12 Basf Ag Verfahren zur Herstellung von direkttablettierbaren Ibuprofen-Formulierungen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502254A (ja) * 1992-09-29 1996-03-12 メルク エンド カンパニー インコーポレーテッド イブプロフェン−ｈ▲下２▼拮抗薬配合物
JP2004536809A (ja) * 2001-06-01 2004-12-09 ポーゼン インコーポレイテッド Ｎｓａｉｄを協調的に送達するための薬剤組成物
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012049800; Ｔｈｅ　Ｎｅｗ　Ｅｎｇｌａｎｄ　Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．３３４，　Ｎｏ．２２, 1996, ｐ．１４３５-１４３９ *
JPN6012049802; 基礎と臨床 Ｖｏｌ．１７，　Ｎｏ．６, 1983, ｐ．１９０５-１９２４ *
JPN6012049803; 基礎と臨床 Ｖｏｌ．１７．　Ｎｏ．８, 1983, ｐ．２６１１-２６１８ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534810A (ja) * 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物
JP2024514989A (ja) * 2021-10-21 2024-04-03 ハン ファ ファーマ カンパニー、リミテッド モンテルカストまたはその薬学的に許容可能な塩、及びレボセチリジンまたはその薬学的に許容可能な塩を含有する、安定性が改善されたフィルムコーティング錠剤

Also Published As

Publication number Publication date
EP2043637A4 (en) 2009-11-25
IL196425A0 (en) 2009-11-18
AU2007275360A1 (en) 2008-01-24
WO2008011426A3 (en) 2008-12-04
PL2043637T3 (pl) 2012-06-29
ES2380747T3 (es) 2012-05-18
EP2438919A1 (en) 2012-04-11
WO2008011426A2 (en) 2008-01-24
CA2657928C (en) 2014-12-02
EP2043637B1 (en) 2012-01-04
EP2043637A2 (en) 2009-04-08
DK2043637T3 (da) 2012-05-07
PT2043637E (pt) 2012-04-12
IL196425A (en) 2014-07-31
EP2043637B8 (en) 2012-03-28
ATE539747T1 (de) 2012-01-15
BRPI0714937A2 (pt) 2013-03-26
AU2007275360B2 (en) 2013-05-16
NZ574200A (en) 2011-02-25
CA2657928A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
US8067451B2 (en) Methods and medicaments for administration of ibuprofen
AU2007275360B2 (en) Methods and medicaments for administration of ibuprofen
US8501228B2 (en) Stable compositions of famotidine and ibuprofen
US20140066485A1 (en) Medicaments containing famotidine and ibuprofen and administration of same
CN101516368B (zh) 用于施用布洛芬的方法和药物
US20080021078A1 (en) Methods and medicaments for administration of ibuprofen
US20150224056A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
US20140322313A1 (en) Pharmaceutical compositions of ibuprofen and an h2 receptor antagonist
AU2006269894B2 (en) Medicaments containing famotidine and ibuprofen and administration of same
US20130236538A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
HK1169038A (en) Compositions comprising famotidine and ibuprofen as well as compositions comprising 25 mg to 28 mg famotidine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110617

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20120425

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130227